AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34939269 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention control group (received intervention later)
Number of subjects: 52
Study 33025927 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing REFIX technology (Regenerador + Sensitive DentalClean, Rabbit Corp)
Number of subjects: 53
Study 35407373 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Rehabilitation System (VRRS)
Number of subjects: 43
Study 35407373 — intervention group
Group type: COMPARATOR
Intervention: Control group (illustrated booklet)
Number of subjects: 43
Study 32441474 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Hormonal Contraceptive (CHC) users
Number of subjects: 170
Study 32441474 — intervention group
Group type: COMPARATOR
Intervention: Non-Combined Hormonal Contraceptive (non-CHC) users
Number of subjects: 170
Study 34817733 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing risks joint model (CR JM)
Number of subjects: 267
Study 34817733 — intervention group
Group type: COMPARATOR
Intervention: Standard joint model (SJM)
Number of subjects: 267
Study 33081849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg twice on first day followed by 400 mg daily for 10 days + Ribavirin (1.2 g loading dose followed by 600 mg every 12 hours for 10 days) + Standard Treatment (STNS)
Number of subjects: 0
Study 33081849 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (STNS)
Number of subjects: 0
Study 33081849 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir (200 mg) + Ritonavir (50 mg) two tablets twice daily + Ribavirin (1.2 g loading dose followed by 600 mg every 12 hours for 10 days) + Standard Treatment (STs)
Number of subjects: 0
Study 33081849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg twice on first day followed by 400 mg daily for 10 days + Ribavirin (1.2 g loading dose followed by 600 mg every 12 hours for 10 days) + Standard Treatment (STs)
Number of subjects: 0
Study 33081849 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (STs)
Number of subjects: 0
Study 36277985 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Lithotripsy (ESWL)
Number of subjects: 90
Study 36277985 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 90
Study 32977992 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 62
Study 32450838 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular treatment interval cohort (3 initial monthly IVT-AFL injections followed by regular injections every 2 months)
Number of subjects: 0
Study 32450838 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular treatment interval cohort with initial doses (3 initial monthly IVT-AFL injections)
Number of subjects: 0
Study 32450838 — intervention group
Group type: COMPARATOR
Intervention: Irregular treatment interval cohort without initial doses
Number of subjects: 0
Study 33104981 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray 55 μg
Number of subjects: 83
Study 33104981 — intervention group
Group type: COMPARATOR
Intervention: Control group without intranasal steroid
Number of subjects: 83
Study 34942176 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-based circulatory management
Number of subjects: 439
Study 34942176 — intervention group
Group type: COMPARATOR
Intervention: BP-based circulatory management (Control)
Number of subjects: 439
Study 34942176 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood flow (BF)
Number of subjects: 439
Study 34942176 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood pressure (BP)
Number of subjects: 439
Study 33835666 — intervention group
Group type: EXPERIMENTAL
Intervention: Immuno-oncology (IO) based systemic treatment
Number of subjects: 0
Study 33835666 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study 32098739 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually-tailored educational videos about maternal and infant vaccines and the cocooning strategy
Number of subjects: 1095
Study 32098739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to receive maternal influenza vaccine, perceived safety of maternal Tdap vaccine, perceived efficacy of maternal influenza vaccine, perceived susceptibility to and severity of influenza during pregnancy, trust in vaccine information from CDC and academic institutions
Number of subjects: 1095
Study 32098739 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty about infant vaccine intentions
Number of subjects: 1095
Study 34581452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved platelets
Number of subjects: 89
Study 34581452 — intervention group
Group type: COMPARATOR
Intervention: Liquid-stored platelets
Number of subjects: 89
Study 33650471 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed (154 patients, 38.1%)
Number of subjects: 404
Study 33650471 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics prescribed (250 patients, 61.9%)
Number of subjects: 404
Study 32580883 — intervention group
Group type: COMPARATOR
Intervention: 27 Gy in five fractions (over 1 week)
Number of subjects: 4096
Study 32580883 — intervention group
Group type: COMPARATOR
Intervention: 26 Gy in five fractions (over 1 week)
Number of subjects: 4096
Study 32580883 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy in 15 fractions (over 3 weeks)
Number of subjects: 4096
Study 35830133 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-suspension of Talaromyces flavus at concentrations of 1, 4, and 5 per thousand (soil addition method)
Number of subjects: 16
Study 35830133 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano-powder of Talaromyces flavus at concentrations of 2 and 3 per thousand (soil addition method)
Number of subjects: 16
Study 35830133 — intervention group
Group type: COMPARATOR
Intervention: Registered formulation of Talaromin (seed impregnation and soil addition methods)
Number of subjects: 16
Study 35830133 — intervention group
Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 16
Study 35830133 — intervention group
Group type: COMPARATOR
Intervention: Infected control
Number of subjects: 16
Study 34089600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (12 weeks of physical exercise training and five psycho‐educational consultations)
Number of subjects: 117
Study 34089600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (exploratory outcomes)
Number of subjects: 117
Study 34089600 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care without rehabilitation)
Number of subjects: 117
Study 33082342 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine therapy (400 mg twice daily for seven days)
Number of subjects: 53
Study 33082342 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 53
Study 35153119 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (0.05 mg/kg) + Atropine (0.02 mg/kg)
Number of subjects: 98
Study 35153119 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (1 mg/kg) after Neostigmine
Number of subjects: 98
Study 34600264 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg twice daily
Number of subjects: 108
Study 34600264 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 108
Study 32811690 — intervention group
Group type: EXPERIMENTAL
Intervention: Front-of-pack labelling and regulated nutrition claims
Number of subjects: 0
Study 33685776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) antimicrobials
Number of subjects: 56
Study 33685776 — intervention group
Group type: COMPARATOR
Intervention: Oral (PO) antimicrobials
Number of subjects: 56
Study 35091076 — intervention group
Group type: EXPERIMENTAL
Intervention: CT+/MSC-
Number of subjects: 4119
Study 35091076 — intervention group
Group type: EXPERIMENTAL
Intervention: CT+/MSC+
Number of subjects: 4119
Study 35091076 — intervention group
Group type: COMPARATOR
Intervention: CT-/MSC-
Number of subjects: 4119
Study 35091076 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-/MSC+
Number of subjects: 4119
Study 33677046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study 33677046 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 570
Study 33677046 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 570
Study 34507611 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 602
Study 34507611 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter
Number of subjects: 602
Study 33395979 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Working Memory Training (EWM-T)
Number of subjects: 106
Study 33395979 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory Training (WM-T)
Number of subjects: 106
Study 33395979 — intervention group
Group type: COMPARATOR
Intervention: Placebo Control
Number of subjects: 106
Study 35609510 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine
Number of subjects: 82
Study 35609510 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 82
Study 34298555 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27564
Study 32645765 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide administration
Number of subjects: 0
Study 32645765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35343585 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin 20 μg
Number of subjects: 277
Study 35343585 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin 100 μg
Number of subjects: 277
Study 35343585 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 0.5 IU
Number of subjects: 277
Study 35343585 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 5 IU
Number of subjects: 277
Study 35343585 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine tone after 5 and 10 minutes, use of additional uterotonics, blood loss and adverse effects
Number of subjects: 277
Study 33037142 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal attainment scaling
Number of subjects: 229
Study 33037142 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROM)
Number of subjects: 229
Study 35834633 — intervention group
Group type: EXPERIMENTAL
Intervention: BSRGE extract (30 mg of GABA per day)
Number of subjects: 41
Study 35834633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 34228017 — intervention group
Group type: EXPERIMENTAL
Intervention: COMprehensive Post-Acute Stroke Services intervention
Number of subjects: 0
Study 34228017 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 35869719 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol combined with remifentanil
Number of subjects: 126
Study 35869719 — intervention group
Group type: COMPARATOR
Intervention: Propofol combined with ketamine
Number of subjects: 126
Study 33910562 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized embryo transfer (pET) guided by RNA‐Seq‐based endometrial receptivity test (rsERT)
Number of subjects: 142
Study 33910562 — intervention group
Group type: COMPARATOR
Intervention: Conventional embryo transfer (ET)
Number of subjects: 142
Study 33910562 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized embryo transfer (pET) guided by rsERT
Number of subjects: 142
Study 35961842 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology treatment along with usual medical care
Number of subjects: 20
Study 35961842 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 20
Study 34388110 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance Training (AvT)
Number of subjects: 45
Study 34388110 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo Training (PT)
Number of subjects: 45
Study 34388110 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach Training (ApT)
Number of subjects: 45
Study 32499757 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (AI) plus weight loss (WL) at 1 mg daily for 6 months
Number of subjects: 23
Study 32499757 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) plus weight loss (WL)
Number of subjects: 23
Study 35151367 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hexose correlated compound (AHCC)
Number of subjects: 230
Study 34948580 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Isometric Relaxation (PIR)
Number of subjects: 60
Study 34948580 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial Release (MR)
Number of subjects: 60
Study 32597013 — intervention group
Group type: EXPERIMENTAL
Intervention: Let's Talk intervention
Number of subjects: 8
Study 32597013 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational capacity
Number of subjects: 8
Study 34875139 — intervention group
Group type: EXPERIMENTAL
Intervention: QR678 Neo® hair growth factor formulation
Number of subjects: 20
Study 32413581 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline only
Number of subjects: 142
Study 32413581 — intervention group
Group type: EXPERIMENTAL
Intervention: varenicline + Prolonged Exposure (PE)
Number of subjects: 142
Study 32413581 — intervention group
Group type: EXPERIMENTAL
Intervention: baseline trauma cognitions
Number of subjects: 142
Study 35680254 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Empowerment Skills (YES) programme
Number of subjects: 50
Study 35680254 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 50
Study 35770601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupping therapy
Number of subjects: 37
Study 35770601 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 37
Study 35102105 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic stable intramedullary nailing (ESIN)
Number of subjects: 40
Study 35102105 — intervention group
Group type: COMPARATOR
Intervention: Submuscular locked plate (SMP)
Number of subjects: 40
Study 32083979 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational Soccer Program (RSP)
Number of subjects: 13
Study 32677375 — intervention group
Group type: EXPERIMENTAL
Intervention: Peramivir 600 mg on two consecutive days (peramivir-repeat)
Number of subjects: 214
Study 32677375 — intervention group
Group type: EXPERIMENTAL
Intervention: Peramivir 300 mg single dose (peramivir-single)
Number of subjects: 214
Study 32677375 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir 75 mg twice daily for 5 days
Number of subjects: 214
Study 32712083 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 30522
Study 34857578 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy alone
Number of subjects: 1900
Study 34857578 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant therapy plus axillary treatment (ANC or axillary RT)
Number of subjects: 1900
Study 34857578 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (standard care)
Number of subjects: 1900
Study 34857578 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm morbidity assessed by Lymphoedema and Breast Cancer Questionnaire and QuickDASH questionnaires
Number of subjects: 1900
Study 34857578 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and anxiety assessed with FACT B+4 and State/Trait Anxiety Inventory questionnaires
Number of subjects: 1900
Study 34857578 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation using EQ-5D-5L
Number of subjects: 1900
Study 36496126 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic-assisted diffusing group
Number of subjects: 30
Study 36496126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic-assisted diffusing group
Number of subjects: 30
Study 36496126 — intervention group
Group type: COMPARATOR
Intervention: Control group (without treatment)
Number of subjects: 30
Study 32684108 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume resistance training (HV-RT)
Number of subjects: 58
Study 32684108 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume resistance training (LV-RT)
Number of subjects: 58
Study 32684108 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isometric voluntary contraction (MIVC)
Number of subjects: 58
Study 32684108 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 58
Study 32510754 — intervention group
Group type: EXPERIMENTAL
Intervention: N. sativa oil (1,000 mg daily for 8 weeks)
Number of subjects: 50
Study 34928294 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose prednisolone (15 mg/m2 daily for 6 days)
Number of subjects: 365
Study 34928294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 34928294 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose prednisolone
Number of subjects: 365
Study 33953213 — intervention group
Group type: EXPERIMENTAL
Intervention: Aiming method (group A)
Number of subjects: 300
Study 33953213 — intervention group
Group type: COMPARATOR
Intervention: Needle guide (group NG)
Number of subjects: 300
Study 34728381 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-ultrasound guided biopsy
Number of subjects: 1200
Study 34728381 — intervention group
Group type: COMPARATOR
Intervention: MRI/US fusion
Number of subjects: 1200
Study 34728381 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI/MicroUS contour-less fusion
Number of subjects: 1200
Study 34728381 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI targeted samples
Number of subjects: 1200
Study 34728381 — intervention group
Group type: EXPERIMENTAL
Intervention: microUS targeted samples
Number of subjects: 1200
Study 34728381 — intervention group
Group type: EXPERIMENTAL
Intervention: systematic samples
Number of subjects: 1200
Study 34728381 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative predictive value of microUS
Number of subjects: 1200
Study 34728381 — intervention group
Group type: COMPARATOR
Intervention: Negative predictive value of MRI
Number of subjects: 1200
Study 34728381 — intervention group
Group type: EXPERIMENTAL
Intervention: Health economic analysis of microUS
Number of subjects: 1200
Study 34728381 — intervention group
Group type: COMPARATOR
Intervention: Health economic analysis of MRI/US fusion
Number of subjects: 1200
Study 33927582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil tablets (250 mg) - various brands
Number of subjects: 6
Study 32197931 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 0
Study 32197931 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation interventions (intensive)
Number of subjects: 0
Study 32197931 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose thoracic CT scan
Number of subjects: 0
Study 32197931 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of smoking cessation and lung cancer screening
Number of subjects: 0
Study 32197931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36065795 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (up to 50 mg/day)
Number of subjects: 513
Study 36065795 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 513
Study 32146715 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression orthosis 23 hours
Number of subjects: 0
Study 32146715 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression orthosis 8 hours
Number of subjects: 0
Study 32146715 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32199866 — intervention group
Group type: EXPERIMENTAL
Intervention: Lampalizumab every 4 weeks
Number of subjects: 1881
Study 32199866 — intervention group
Group type: EXPERIMENTAL
Intervention: Lampalizumab every 6 weeks
Number of subjects: 1881
Study 32199866 — intervention group
Group type: COMPARATOR
Intervention: Sham every 4 weeks
Number of subjects: 1881
Study 32199866 — intervention group
Group type: COMPARATOR
Intervention: Sham every 6 weeks
Number of subjects: 1881
Study 32199866 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1881
Study 32199866 — intervention group
Group type: EXPERIMENTAL
Intervention: Microperimetry outcomes
Number of subjects: 1881
Study 36209245 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg in 100 ml isotonic saline)
Number of subjects: 60
Study 36209245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 ml isotonic saline only)
Number of subjects: 60
Study 33422517 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate invasive strategy (<3 hours)
Number of subjects: 249
Study 33422517 — intervention group
Group type: COMPARATOR
Intervention: Early invasive strategy (12‐24 hours)
Number of subjects: 249
Study 33422517 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate invasive strategy
Number of subjects: 249
Study 33422517 — intervention group
Group type: COMPARATOR
Intervention: Early invasive strategy
Number of subjects: 249
Study 32321483 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative Care Intervention (PCI) integrated with standard haematological care
Number of subjects: 60
Study 32321483 — intervention group
Group type: COMPARATOR
Intervention: Standard haematological care alone
Number of subjects: 60
Study 35436810 — intervention group
Group type: EXPERIMENTAL
Intervention: Subanesthetic dose of esketamine 0.125 mg·kg‐1·h‐1 (group ES1)
Number of subjects: 71
Study 35436810 — intervention group
Group type: EXPERIMENTAL
Intervention: Subanesthetic dose of esketamine 0.250 mg·kg‐1·h‐1 (group ES2)
Number of subjects: 71
Study 35436810 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control group C)
Number of subjects: 71
Study 35279940 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharide isomerate
Number of subjects: 0
Study 35279940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33144386 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway clearance techniques (20 min of prolonged slow expiration and provoked cough)
Number of subjects: 91
Study 33144386 — intervention group
Group type: COMPARATOR
Intervention: High-frequency chest wall compression (HFCWC) (15 min)
Number of subjects: 91
Study 35016205 — intervention group
Group type: EXPERIMENTAL
Intervention: DAV132 (7.5 g, 3 times a day, orally)
Number of subjects: 243
Study 35016205 — intervention group
Group type: COMPARATOR
Intervention: No-DAV132
Number of subjects: 243